Biodexa Pharmaceuticals plc (BDRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BDRX SEC filings page.
This page shows Biodexa Pharmaceuticals plc (BDRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Biodexa Pharmaceuticals plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Biodexa Pharmaceuticals plc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
Biodexa Pharmaceuticals plc reported a net loss of $8.6M while operations used $7.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Biodexa Pharmaceuticals plc reported an operating loss of $11.6M against $308K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Biodexa Pharmaceuticals plc reported a net loss of $8.6M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Biodexa Pharmaceuticals plc earned $0.00 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Biodexa Pharmaceuticals plc recorded an outflow of $7.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Biodexa Pharmaceuticals plc held $11.5M in cash against $0 in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Biodexa Pharmaceuticals plc's ROE was -56.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 12.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Biodexa Pharmaceuticals plc invested $5.3M in research and development in fiscal year 2025. This represents a decrease of 21.8% from the prior year.
Biodexa Pharmaceuticals plc invested $3K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 76.1% from the prior year.
Not reported for fiscal year 2025.
BDRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $486K-42.5% | $844K+8.2% | $780K+66.5% | $469K-47.6% | $894K-63.8% | $2.5M+84.9% | $1.3M-18.0% | $1.6M-19.5% | $2.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.3M+52.2% | $823K+697.2% | $103K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $85K-89.5% | $809K-57.9% | $1.9M |
| R&D Expenses | $5.3M-21.8% | $6.8M+31.4% | $5.2M-16.0% | $6.2M-1.8% | $6.3M-24.2% | $8.3M-20.3% | $10.4M-12.9% | $11.9M+6.0% | $11.3M+18.2% | $9.5M-25.7% | $12.8M |
| Operating Income | -$11.6Mn/m | -$11.5Mn/m | -$10.2Mn/m | -$10.8Mn/m | -$9.4Mn/m | -$31.5Mn/m | -$15.0Mn/m | -$15.1Mn/m | -$18.0Mn/m | -$11.9Mn/m | -$19.0M |
| Interest Expense | $308K+49.1% | $207K+295.4% | $52K-18.4% | $64K+7.8% | $59K-89.9% | $589K+357.5% | $129K-82.8% | $749K+233.6% | $225K+149.4% | $90K+1121.5% | $7K |
| Income Tax | -$141Kn/m | -$313Kn/m | -$517Kn/m | -$1.0Mn/m | -$872Kn/m | -$1.8M-173.9% | $2.4Mn/m | -$2.6Mn/m | -$1.7Mn/m | -$2.7Mn/m | -$1.7M |
| Net Income | -$8.6Mn/m | -$7.2Mn/m | -$9.0Mn/m | -$9.2Mn/m | -$7.4Mn/m | -$30.3Mn/m | -$13.4Mn/m | -$19.2Mn/m | -$21.7Mn/m | -$24.9Mn/m | -$14.9M |
| EPS (Basic) | $0.00 | $0.00 | -$0.03 | -$1.87 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | $0.00 | $0.00 | -$0.03 | -$1.87 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: SG&A Expenses, EBITDA, Diluted Shares (Avg).
BDRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $24.4M+32.1% | $18.5M+37.8% | $13.4M+101.3% | $6.7M-61.7% | $17.4M+30.0% | $13.4M-67.3% | $41.0M+57.1% | $26.1M-60.8% | $66.6M-4.8% | $69.9M-25.9% | $94.4M |
| Current Assets | $16.7M+51.7% | $11.0M+23.1% | $9.0M+58.2% | $5.7M-64.3% | $15.9M+25.3% | $12.7M-30.5% | $18.2M+154.2% | $7.2M-71.5% | $25.1M-8.6% | $27.5M-8.2% | $30.0M |
| Cash & Equivalents | $11.5M+449.1% | $2.1M-72.5% | $7.6M+122.2% | $3.4M-74.8% | $13.6M+31.7% | $10.3M-28.9% | $14.5M+384.9% | $3.0M-83.3% | $17.9M-17.8% | $21.7M-8.9% | $23.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.3M+26.3% | $1.0M+48.9% | $677K |
| Accounts Receivable | $5.1M-38.1% | $8.2M+913.1% | $812K-33.2% | $1.2M-13.0% | $1.4M+78.6% | $781K-40.6% | $1.3M-22.0% | $1.7M-61.5% | $4.4M+45.8% | $3.0M-18.2% | $3.7M |
| Goodwill | $7.6M+7.4% | $7.1M+88.6% | $3.7M+51619.7% | $7K | N/A | $0-100.0% | $3.1M+4.0% | $2.9M-83.8% | $18.1M-46.8% | $34.1M-44.0% | $61.0M |
| Total Liabilities | $9.1M+12.7% | $8.1M+8.2% | $7.5M+161.8% | $2.9M-14.1% | $3.3M-21.5% | $4.2M-71.9% | $15.0M+234.8% | $4.5M-77.2% | $19.7M+45.5% | $13.5M-46.5% | $25.3M |
| Current Liabilities | $8.2M+30.8% | $6.3M-11.2% | $7.1M+209.3% | $2.3M-7.7% | $2.5M-39.1% | $4.1M-45.7% | $7.5M+138.4% | $3.2M-72.1% | $11.3M-1.9% | $11.5M-14.1% | $13.4M |
| Non-Current Liabilities | $867K-51.4% | $1.8M+374.3% | $376K-32.8% | $559K-33.2% | $837K+457.0% | $150K-98.0% | $7.5M+461.9% | $1.3M-84.0% | $8.4M+318.7% | $2.0M-83.2% | $11.9M |
| Long-Term Debt | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $1.1M-86.5% | $8.4M+318.7% | $2.0M-10.1% | $2.2M |
| Total Equity | $15.3M+47.2% | $10.4M+74.8% | $6.0M+56.1% | $3.8M-72.9% | $14.1M+53.7% | $9.2M-64.6% | $26.0M+20.1% | $21.6M-54.0% | $46.9M-16.8% | $56.4M-18.4% | $69.1M |
| Retained Earnings | -$209.5Mn/m | -$188.3Mn/m | -$184.5Mn/m | -$163.4Mn/m | -$172.5Mn/m | -$167.3Mn/m | -$132.5Mn/m | -$114.5Mn/m | -$101.0Mn/m | -$72.9Mn/m | -$57.7M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
BDRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.5Mn/m | -$15.4Mn/m | -$8.7Mn/m | -$8.5Mn/m | -$8.1Mn/m | -$12.7Mn/m | -$8.6Mn/m | -$17.2Mn/m | -$17.5Mn/m | -$16.1Mn/m | -$18.3M |
| Capital Expenditures | $3K-76.1% | $11K-66.0% | $33K-55.8% | $75K-82.7% | $432K+51.3% | $286K-30.6% | $411K+32.1% | $311K-67.4% | $957K-42.4% | $1.7M+22.2% | $1.4M |
| Free Cash Flow | -$7.5Mn/m | -$15.4Mn/m | -$8.7Mn/m | -$8.6Mn/m | -$8.5Mn/m | -$13.0Mn/m | -$9.0Mn/m | -$17.5Mn/m | -$18.5Mn/m | -$17.8Mn/m | -$19.7M |
| Investing Cash Flow | -$784Kn/m | -$749Kn/m | -$338Kn/m | -$266Kn/m | -$375K-110.7% | $3.5Mn/m | -$5.1M-143.8% | $11.5Mn/m | -$2.0Mn/m | -$1.5Mn/m | -$2.3M |
| Financing Cash Flow | $17.5M+63.6% | $10.7M-17.8% | $13.0M+22857.3% | $57K-99.5% | $11.9M+182.1% | $4.2M-83.0% | $24.9Mn/m | -$8.3M-159.4% | $13.9M-26.1% | $18.8Mn/m | -$323K |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
BDRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6.4%-43.2pp | 49.6%-45.3pp | 94.9% |
| Operating Margin | N/A | N/A | -2103.4% | -1277.8% | -1210.7% | -6717.2% | -1679.2% | -609.6% | -1342.4% | -729.6% | -939.5% |
| Net Margin | N/A | N/A | -1858.0% | -1095.3% | -944.6% | -6469.1% | -1496.3% | -775.5% | -1624.3% | -1524.0% | -734.5% |
| Return on Equity | -56.0%+12.9pp | -68.8%+82.5pp | -151.3%+90.8pp | -242.1%-189.9pp | -52.2%+278.1pp | -330.3%-278.7pp | -51.6%+37.3pp | -88.8%-42.5pp | -46.3%-2.2pp | -44.1%-22.6pp | -21.5% |
| Return on Assets | -35.1%+3.6pp | -38.8%+28.4pp | -67.2%+71.4pp | -138.6%-96.3pp | -42.3%+183.7pp | -226.0%-193.4pp | -32.6%+40.9pp | -73.5%-40.9pp | -32.6%+2.9pp | -35.6%-19.8pp | -15.8% |
| Current Ratio | 2.03+0.3x | 1.75+0.5x | 1.26-1.2x | 2.47-3.9x | 6.39+3.3x | 3.10+0.7x | 2.42+0.2x | 2.27+0.1x | 2.22-0.2x | 2.39+0.2x | 2.23 |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00-0.1x | 0.05-0.1x | 0.18+0.1x | 0.040.0x | 0.03 |
| Liabilities-to-Equity | 0.59-0.2x | 0.78-0.5x | 1.25+0.5x | 0.75+0.5x | 0.24-0.2x | 0.46-0.1x | 0.58+0.4x | 0.21-0.2x | 0.42+0.2x | 0.24-0.1x | 0.37 |
| Asset Turnover | N/A | N/A | 0.04-0.1x | 0.13+0.1x | 0.040.0x | 0.030.0x | 0.02-0.1x | 0.09+0.1x | 0.020.0x | 0.020.0x | 0.02 |
| FCF Margin | N/A | N/A | -1798.4% | -1017.2% | -1094.8% | -2772.6% | -1008.8% | -706.6% | -1381.2% | -1090.9% | -970.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Biodexa Pharmaceuticals plc BDRX | FY2025 | N/A | -$8.6M | N/A | $913K | — |
| Dermata Therapeutics, Inc. DRMA | FY2025 | N/A | -$7.6M | N/A | $4.0M | — |
| Silexion Therapeutics Corp SLXN | FY2025 | $155K | -$11.9M | N/A | $2.4M | — |
Where Biodexa Pharmaceuticals plc Ranks
Frequently Asked Questions
Is Biodexa Pharmaceuticals plc profitable?
No, Biodexa Pharmaceuticals plc (BDRX) reported a net loss of $8.6M in fiscal year 2025.
How much debt does Biodexa Pharmaceuticals plc have?
As of fiscal year 2025, Biodexa Pharmaceuticals plc (BDRX) had $11.5M in cash and equivalents against $0 in long-term debt.
What is Biodexa Pharmaceuticals plc's return on equity (ROE)?
Biodexa Pharmaceuticals plc (BDRX) has a return on equity of -56.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biodexa Pharmaceuticals plc's free cash flow?
Biodexa Pharmaceuticals plc (BDRX) recorded an outflow of $7.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biodexa Pharmaceuticals plc's operating cash flow?
Biodexa Pharmaceuticals plc (BDRX) recorded an outflow of $7.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Biodexa Pharmaceuticals plc's total assets?
Biodexa Pharmaceuticals plc (BDRX) had $24.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biodexa Pharmaceuticals plc's capital expenditures?
Biodexa Pharmaceuticals plc (BDRX) invested $3K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biodexa Pharmaceuticals plc spend on research and development?
Biodexa Pharmaceuticals plc (BDRX) invested $5.3M in research and development during fiscal year 2025.
What is Biodexa Pharmaceuticals plc's current ratio?
Biodexa Pharmaceuticals plc (BDRX) had a current ratio of 2.03 as of fiscal year 2025, which is generally considered healthy.
What is Biodexa Pharmaceuticals plc's debt-to-equity ratio?
Biodexa Pharmaceuticals plc (BDRX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Biodexa Pharmaceuticals plc's liabilities-to-equity ratio?
Biodexa Pharmaceuticals plc (BDRX) had a liabilities-to-equity ratio of 0.59 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Biodexa Pharmaceuticals plc's return on assets (ROA)?
Biodexa Pharmaceuticals plc (BDRX) had a return on assets of -35.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biodexa Pharmaceuticals plc's P/E ratio?
Biodexa Pharmaceuticals plc (BDRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $913K as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Biodexa Pharmaceuticals plc's price-to-sales ratio?
Biodexa Pharmaceuticals plc (BDRX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $913K as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Biodexa Pharmaceuticals plc's Piotroski F-Score?
Biodexa Pharmaceuticals plc (BDRX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biodexa Pharmaceuticals plc's earnings high quality?
Biodexa Pharmaceuticals plc (BDRX) reported a net loss of $8.6M while operations used $7.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biodexa Pharmaceuticals plc cover its interest payments?
Biodexa Pharmaceuticals plc (BDRX) reported an operating loss of $11.6M against $308K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.